CIT2020|Online Release Conference of MemoLefort® Left Atrial Appendage (LAA) Closure Occluder I A Great Success: Domestic Apparatus Offers Aid in ‘Domestication’ of LAA Closure

This online press conference invited Professor Cao Kejiang from Jiangsu Provincial People's Hospital, Professor Fang Weiyi, Dean of Hefei High-tech Cardiovascular Hospital under Lepu Medical, Professor Huang He from Wuhan University People's Hospital, and Professor Zhang Shu from Fuwai Hospital, Chinese Academy of Medical Sciences as chairmen, and invited Professor Chen Wei from the Tenth People's Hospital of Tongji University, Professor Niu Guodong from Fuwai Hospital of Chinese Academy of Medical Sciences, and Professor Zhou Daxin from Zhongshan Hospital of Fudan University to give wonderful keynote speeches. (In sequence of pinyin of surname)

Clinical trials and application prospects of MemoLefort®LAA Closure Occluder I

On behalf of Professor Zhang Shu's team, Professor Niu Guodong from Fuwai Hospital of Chinese Academy of Medical Sciences shared a report on clinical trial and application prospects of MemoLefort® LAA Closure Occluder I. As team leader of  clinical trial, Professor Niu Guodong highly spoke of excellent results of the MemoLefort LAA Closure Occluder I in clinical trial. He also mentioned that due to  further acceleration of China's aging problem, the number of patients with atrial fibrillation in China will continue to rise in days to come and proportion of strokes will also be on ascendance. So development prospects of LAA occluder in China are  broad. President Fang Youyi also affirmed safety and effectiveness of MemoLefort LAA Occluder in his comments, and believed that emergence of this product would bring bliss to Chinese patients with atrial fibrillation.

Key points and operation skills of transseptal puncture

Professor Zhou Daxin from Zhongshan Hospital affiliated to Fudan University shared relevant experience on key points and techniques of transseptal puncture. He also mentioned that in actual use of MemoLefort LAA closure occluder I, clinical operation was convenient, sheath can be well coaxial with LAA during implants and occluder has good compliance after implantation. In clinical trials, occlusion was complete with no residual shunt. In his comments, Professor Fang Weiyi likened transatrial septal puncture to a key for ‘precise target’ in LAA closure surgery. He also aspired that Professor Zhou Daxin could share more relevant experience thanks to its  instructive significance for learning of this new technology among clinicians.

Experience Sharing of Single Center of MemoLefort®LAA Closure Occluder I

On behalf of Professor Xu Yawei's team in the tenth People's Hospital of Tongji University, center with most clinical trials of MemoLefort® LAA Closure Occluder I , Professor Chen Wei elaborated single-center application experience of MemoLefort LAA Occluder I. Professor Chen Wei mentioned that MemoLefort LAA Closure Occluder I could match similar products in the success rate of occlusion, stroke and related complications, and featured high safety and effectiveness. Professor Fang Youyi also gave his thumbs-up in his comments to MemoLefort® LAA Closure Occluder I is a reliable domestic occluder.

Good performance with a promising future

Stroke prevention is a major task in comprehensive management of atrial fibrillation. As an emerging device-based antithrombotic therapy, LAA occlusion is going through vigorous development after entering China, but standardization of its diagnosis and treatment process and large-scale promotion and application still calls for steady advancement in exploration and improvement. As a medical device manufacturer in related fields, SHSMA will actively cooperate with clinicians to combine mature technical concepts and high-quality products together to jointly promote healthy development of atrial fibrillation treatment and LAA closure in China so as to provide patients with more benefits.